{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:16:25Z","timestamp":1789913785601,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM15\/00188"],"award-info":[{"award-number":["CM15\/00188"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008425","name":"Xunta de Galicia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejps.2018.04.038","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T14:12:38Z","timestamp":1524751958000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Preclinical characterization and clinical evaluation of tacrolimus eye drops"],"prefix":"10.1016","volume":"120","author":[{"given":"Andrea","family":"Luaces-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Touri\u00f1o-Peralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Alonso-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xurxo","family":"Garc\u00eda-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonz\u00e1lez-Barcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Rodr\u00edguez-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"G\u00f3mez-Lado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Silva-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Ruibal-Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Otero-Espinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7348-7337","authenticated-orcid":false,"given":"Anxo","family":"Fern\u00e1ndez-Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.04.038_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0974-9233.164616","article-title":"Tacrolimus ointment for treatment of vernal keratoconjunctivitis","volume":"23","author":"Al-Amri","year":"2016","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.drudis.2013.10.001","article-title":"In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations","volume":"19","author":"Almeida","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2018.04.038_bb0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1087057105279635","article-title":"Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays","volume":"10","author":"Atienza","year":"2005","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ejps.2018.04.038_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":"Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study","volume":"33","author":"Attas-Fox","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1442-9071.2008.01803.x","article-title":"Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells","volume":"36","author":"Ayaki","year":"2008","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0030","series-title":"Allergic Diseases of the Eye","first-page":"35","author":"Bielory","year":"2016"},{"key":"10.1016\/j.ejps.2018.04.038_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.ejps.2018.04.038_bb0040","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/17425255.2016.1209481","article-title":"Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)","volume":"12","author":"Bonniard","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.snb.2006.10.024","article-title":"Real-time assessment of cytotoxicity by impedance measurement on a 96-well plate","volume":"123","author":"Ceriotti","year":"2007","journal-title":"Sensors Actuators B Chem."},{"key":"10.1016\/j.ejps.2018.04.038_bb0050","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.fct.2011.11.040","article-title":"Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor","volume":"50","author":"Chen","year":"2012","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0055","first-page":"51","article-title":"Ocular manifestations of allergic and immunologic diseases","author":"Christensen","year":"2017","journal-title":"SpringerLink"},{"key":"10.1016\/j.ejps.2018.04.038_bb0060","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1023\/A:1015813225804","article-title":"Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions","volume":"8","author":"Davies","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0065","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.jaci.2004.01.077","article-title":"Vernal keratoconjunctivitis","volume":"113","author":"Dumrongkigchaiporn","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2332\/allergolint.11-OA-0349","article-title":"Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% Tacrolimus ophthalmic suspension","volume":"61","author":"Ebihara","year":"2012","journal-title":"Allergol. Int."},{"key":"10.1016\/j.ejps.2018.04.038_bb0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1566524015666150731095426","article-title":"Ocular inflammatory diseases: molecular pathogenesis and immunotherapy","volume":"15","author":"Egwuagu","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejps.2018.04.038_bb0080","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2146\/ajhp160169","article-title":"Stability of tacrolimus ophthalmic solution","volume":"74","author":"Ezquer-Garin","year":"2017","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0085","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijpharm.2015.09.058","article-title":"Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention","volume":"495","author":"Fern\u00e1ndez-Ferreiro","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0090","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijpharm.2015.09.058","article-title":"Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention","volume":"495","author":"Fern\u00e1ndez-Ferreiro","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0095","series-title":"Farm. Hosp. Organo Of. Expresion Cient. Soc. Espanola Farm. Hosp","first-page":"352","article-title":"Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the hospital pharmacy departments","volume":"40","author":"Fern\u00e1ndez-Ferreiro","year":"2016"},{"key":"10.1016\/j.ejps.2018.04.038_bb0100","first-page":"772","article-title":"Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations","volume":"58","author":"Fern\u00e1ndez-Ferreiro","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0105","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jfo.2012.03.019","article-title":"Galenic and analytic development of tacrolimus 0.06% eye drops","volume":"36","author":"Gauthier","year":"2013","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0115","first-page":"1","article-title":"Roles of IL-6 in ocular inflammation: a review","volume":"0","author":"Ghasemi","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2010.09.015","article-title":"Molecular imaging with SPECT as a tool for drug development","volume":"63","author":"Gomes","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.04.038_bb0125","first-page":"379","article-title":"Tacrolimus","author":"Greiner","year":"2016","journal-title":"SpringerLink"},{"key":"10.1016\/j.ejps.2018.04.038_bb0130","first-page":"19","article-title":"Preparation of tacrolimus ophthalmic solution using cyclodextrins","volume":"24","author":"Hajiahmadi","year":"2017","journal-title":"J. Birjand Univ. Med. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0135","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20345","volume":"63","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3959(01)00314-1","article-title":"The faces pain scale \u2013 revised: toward a common metric in pediatric pain measurement","volume":"93","author":"Hicks","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2018.04.038_bb0145","author":"International Conference on Harmonisation (ICH)"},{"key":"10.1016\/j.ejps.2018.04.038_bb0150","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(14)72551-6","article-title":"FK506 treatment of noninfectious uveitis","volume":"118","author":"Ishioka","year":"1994","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/ICO.0b013e31820cd607","article-title":"Cyclosporine a 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis","volume":"30","author":"Jeng","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.ejps.2018.04.038_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.2006.097428","article-title":"Tacrolimus immunosuppression in high-risk corneal grafts","volume":"91","author":"Joseph","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0165","first-page":"1738","article-title":"Characterization of cyclosporin a transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin","volume":"40","author":"Kawazu","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0170","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ejps.2018.04.038_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2231-4040.85540","article-title":"Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment","volume":"2","author":"Kumar","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine a delivery to the eye: a comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV"},{"key":"10.1016\/j.ejps.2018.04.038_bb0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ophtha.2015.10.011","article-title":"Long-term natural history of dry eye disease from the Patient's perspective","volume":"123","author":"Lienert","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejps.2018.04.038_bb0190","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2018.04.038_bb0195","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ijpharm.2017.06.060","article-title":"Cysteamine polysaccharide hydrogels: study of extended ocular delivery and biopermanence time by PET imaging","volume":"528","author":"Luaces-Rodr\u00edguez","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0200","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/bjophthalmol-2013-303639","article-title":"Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study","volume":"97","author":"Magalhaes","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0002-9394(14)73645-1","article-title":"A clinical trial of FK506 in refractory uveitis","volume":"115","author":"Mochizuki","year":"1993","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bjo.2007.121533","article-title":"Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid","volume":"92","author":"Mochizuki","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0215","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.ejps.2018.04.038_bb0220","series-title":"The National Academies Collection: Reports funded by National Institutes of Health","article-title":"Guide for the care and use of laboratory animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1016\/j.ejps.2018.04.038_bb0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-001-0424-0","article-title":"Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506","volume":"240","author":"Nishino","year":"2002","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0230","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1167\/iovs.13-11717","article-title":"Analysis of ethanol effects on corneal epithelium","volume":"54","author":"Oh","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.04.038_bb0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5935\/0004-2749.20150078","article-title":"Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits","volume":"78","author":"Parrilha","year":"2015","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0245","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3109\/02713683.2015.1082187","article-title":"Evaluation of the ocular tolerance of three Tacrolimus topical pharmaceutical preparations by bovine corneal opacity and permeability test","volume":"41","author":"Pastor-Clerigues","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: An overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"issue":"146","key":"10.1016\/j.ejps.2018.04.038_bb0255","first-page":"2374","article-title":"FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells","volume":"1950","author":"de Paulis","year":"1991","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.ejps.2018.04.038_bb0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0939-6411(96)00010-0","article-title":"Ultrapure poly(vinyl alcohol) hydrogels with mucoadhesive drug delivery characteristics","volume":"43","author":"Peppas","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.038_bb0265","unstructured":"Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis - Full Text View - ClinicalTrials.gov [WWW Document], (2014) URL https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00567762 (accessed 8.17.17)."},{"key":"10.1016\/j.ejps.2018.04.038_bb0270","first-page":"2737","article-title":"Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye","volume":"34","author":"Pleyer","year":"1993","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0275","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5935\/0034-7280.20160087","article-title":"Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky score: a cross sectional study","volume":"75","author":"Ribeiro","year":"2016","journal-title":"Rev. Bras. Oftalmol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0280","series-title":"The Pharmaceutical Codex: Principles and Practice of Pharmaceutics, Twelfth","author":"Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical","year":"1994"},{"key":"10.1016\/j.ejps.2018.04.038_bb0285","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.135.5.574","article-title":"Tacrolimus: the drug for the turn of the millennium?","volume":"135","author":"Ruzicka","year":"1999","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejps.2018.04.038_bb0290","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1023\/A:1011956327987","article-title":"Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line","volume":"15","author":"Saarinen-Savolainen","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0295","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1167\/iovs.07-0229","article-title":"Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation","volume":"48","author":"Said","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0300","doi-asserted-by":"crossref","DOI":"10.1186\/s40662-017-0072-z","article-title":"Topical tacrolimus in anterior segment inflammatory disorders","volume":"4","author":"Shoughy","year":"2017","journal-title":"Eye Vis."},{"key":"10.1016\/j.ejps.2018.04.038_bb0305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OPTH.S99157","article-title":"Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis","volume":"10","author":"Shoughy","year":"2016","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"10.1016\/j.ejps.2018.04.038_bb0310","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(01)00759-X","article-title":"Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts","volume":"108","author":"Sloper","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejps.2018.04.038_bb0315","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00003226-199207000-00003","article-title":"Ocular surface residence times of artificial tear solutions","volume":"11","author":"Snibson","year":"1992","journal-title":"Cornea"},{"key":"10.1016\/j.ejps.2018.04.038_bb0320","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S101627","article-title":"The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye","volume":"10","author":"Stonecipher","year":"2016","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"10.1016\/j.ejps.2018.04.038_bb0325","author":"The Association for Research in Vision and Ophthalmology"},{"key":"10.1016\/j.ejps.2018.04.038_bb0330","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1167\/iovs.15-16444","article-title":"Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases","volume":"56","author":"Thompson","year":"2015","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0335","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11745-997-0069-1","article-title":"The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation","volume":"32","author":"Uno","year":"1997","journal-title":"Lipids"},{"key":"10.1016\/j.ejps.2018.04.038_bb0340","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11882-013-0345-0","article-title":"Use of cyclosporine a and tacrolimus in treatment of vernal keratoconjunctivitis","volume":"13","author":"Vichyanond","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.ejps.2018.04.038_bb0345","first-page":"932","article-title":"Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis","volume":"17","author":"Wakamatsu","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejps.2018.04.038_bb0350","first-page":"221","article-title":"Determination of tacrolimus ophthalmic emulsion by HPLC","volume":"45","author":"Wan","year":"2010","journal-title":"J. Chin. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.038_bb0355","series-title":"Pharmacologic Therapy of Ocular Disease, Handbook of Experimental Pharmacology","year":"2017"},{"key":"10.1016\/j.ejps.2018.04.038_bb0360","doi-asserted-by":"crossref","DOI":"10.1023\/A:1026471020698","article-title":"The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS","volume":"6","author":"Wu","year":"1997","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ejps.2018.04.038_bb0365","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.tiv.2005.12.008","article-title":"Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity","volume":"20","author":"Xing","year":"2006","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.ejps.2018.04.038_bb0370","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jop.2008.0125","article-title":"Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration","volume":"25","author":"Yuan","year":"2009","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.04.038_bb0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/jop.2011.0108","article-title":"Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation","volume":"28","author":"Yuan","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.04.038_bb0380","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0168-3659(98)00150-3","article-title":"Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate","volume":"57","author":"Yura","year":"1999","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejps.2018.04.038_bb0385","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/ICO.0000000000001200","article-title":"Comparative evaluation of Tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal Keratoconjunctivitis: a randomized, double-masked study","volume":"36","author":"Zanjani","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.ejps.2018.04.038_bb0390","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.colsurfb.2016.01.014","article-title":"Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability","volume":"141","author":"Zeng","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ejps.2018.04.038_bb0395","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:47:48Z","timestamp":1760528868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718302033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":79,"alternative-id":["S0928098718302033"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.04.038","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization and clinical evaluation of tacrolimus eye drops","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}